Arvinas (ARVN) grants CMO 67,000 options and 45,000 RSUs

Rhea-AI Filing Summary

ARVINAS, INC. reported that Chief Medical Officer Noah Berkowitz received new equity awards. He was granted stock options for 67,000 shares at an exercise price of $0.0000 per share and 45,000 restricted stock units, each representing one share of common stock upon settlement for no consideration.

The RSUs vest in four equal annual installments on February 26, 2027, 2028, 2029 and 2030, subject to continued service. The option also vests over four years, with one-quarter vesting on February 26, 2027 and the remainder in equal monthly installments through February 26, 2030. Following these grants, Berkowitz directly owns 208,938 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Berkowitz Noah

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	67,000	$0.00	--
Grant/Award	Common Stock	45,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 67,000 shares (Direct); Common Stock — 208,938 shares (Direct)

Footnotes (1)

1. The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/02/2026 - 08:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berkowitz Noah

(Last) (First) (Middle)

C/O ARVINAS, INC.

5 SCIENCE PARK, 395 WINCHESTER AVE.

(Street)

NEW HAVEN CT 06511

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		45,000(1)	A	$0	208,938	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.38	02/26/2026		A		67,000		(2)	02/25/2036	Common Stock	67,000	$0	67,000	D

Explanation of Responses:

1. The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

2. The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date.

Remarks:

	/s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did ARVN grant to its Chief Medical Officer?

Arvinas granted its Chief Medical Officer 67,000 stock options and 45,000 restricted stock units. Each RSU represents one share of common stock upon settlement for no consideration, reflecting a significant component of his long-term incentive compensation.

How do the new restricted stock units for ARVN’s CMO vest?

The 45,000 restricted stock units vest in four equal annual installments starting February 26, 2027. Additional tranches vest on February 26, 2028, 2029, and 2030, provided the executive continues serving the company on each vesting date.

What is the vesting schedule for the 67,000 stock options granted by ARVN?

One-quarter of the 67,000 stock options vests on February 26, 2027. The remaining three-quarters then vest in equal monthly installments from that date through February 26, 2030, contingent on continued employment with Arvinas.

At what price were the new ARVN stock options granted to the CMO?

The 67,000 stock options were granted with a per-share exercise price of $0.0000. This reflects a typical incentive structure where value depends on future stock performance rather than an upfront purchase by the executive.

How many ARVN common shares does the CMO own after these grants?

After the reported transactions, the Chief Medical Officer directly owns 208,938 shares of Arvinas common stock. This total reflects his updated direct beneficial ownership following the February 26, 2026 equity awards.

Under which plan were ARVN’s new options and RSUs granted?

Both the stock options and restricted stock units were granted under Arvinas’ 2018 Stock Incentive Plan. This plan governs the terms, vesting schedules, and conditions tied to the executive’s continued service with the company.